Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,032.00
Ask: 12,036.00
Change: 98.00 (0.82%)
Spread: 4.00 (0.033%)
Open: 12,108.00
High: 12,142.00
Low: 11,994.00
Prev. Close: 11,930.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks slip as US jobless claims fall

Thu, 08th Feb 2024 14:42

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

AstraZeneca shares also dropped following the release of its results.

The FTSE 100 closed down 0.44% at 7,595.48 points, while the FTSE 250 saw a more marginal decrease of 0.01% to reach 19,102.72 points.

In currency markets, sterling was last down 0.05% on the dollar to trade at $1.2620, while it weakened 0.09% against the euro to change hands at €1.1711.

"A big drop for AstraZeneca has wiped 40 points off the FTSE 100 today, with the result that the index has been left behind as other European markets make headway today," said IG chief market analyst Chris Beauchamp.

"Astra's poor performance since the summer has been a key driver for the FTSE 100's inability to keep up with its peers, and today's numbers suggest that weight will continue for the time being."

Beauchamp added that the S&P 500 failed to hit 5,000 by "the slimmest of margins" on Wednesday, but said it was only a matter of time.

"While it might seem outlandish, a Dow 40,000 might not be too far behind, especially if the market continues in its present frame of mind.

"Crucially, indices have remained solid despite the latest strong US data and the diminishing chance of a March cut, showing that there is more to this rally than just hopes of a looser policy environment."

US jobless claims fall more than expected

In economic news, fresh data from the Labor Department showed Americans filed for unemployment benefits at a slower pace for the week ended 2 February.

Initial jobless claims decreased by 9,000 to 218,000, slightly below the anticipated 220,000 mark.

The figure, while indicative of a slowing trend, still suggested a resilient labour market.

Continuing claims also saw a decline, dropping by 23,000 to 1.87 million in the last week of January.

However, the four-week moving average increased by 3,750 to 212,250.

Non-seasonally adjusted claims experienced a notable decrease of 31,192 to 232,727, with some states such as Oregon, Ohio, and California reporting declines, while Missouri and Texas noted increases.

On home shores, the UK housing market showed signs of stabilisation in January, according to the latest UK Residential Market Survey from the Royal Institution of Chartered Surveyors.

Buyer demand, agreed sales, and new instructions all strengthened last month, buoyed by hopes of a potential interest rate cut.

New buyer enquiries saw a notable increase, reaching a balance of 7, the highest since February 2022.

Agreed sales also entered positive territory, rising to 5 from -5.

Respondents expressed optimism for future conditions, with expectations of further improvement in sales over the next three and 12 months.

Although house prices remained in negative territory at -18, it marked a significant improvement from December's figure of -30, indicating a more optimistic outlook amidst economic uncertainties.

"The UK housing market has seen a continued improvement in buyer activity through the early part of the year, supported by the recent easing in mortgage rates," said Tarrant Parsons, senior economist at RICS.

"Although sales volumes through much of the year ahead are likely to remain relatively subdued compared to the longer-term average, the outlook has now turned modestly brighter on a consistent basis over the past few survey reports.

"However, this is not to say that mortgage affordability isn't still a significant challenge, and any further unwelcome surprises with regards to inflation may still cause interest rates expectations to be revised."

However, amid the positive indicators there were concerns around the UK mortgage market, as the number of mortgages in arrears increased 7% in the fourth quarter of 2023, with homeowner mortgages seeing a rise from the prior quarter and year.

Buy-to-let mortgages also experienced an 18% increase from the previous quarter and a substantial 124% rise from the previous year.

The number of homes repossessed decreased, with just 540 homeowner mortgages and 500 buy-to-let properties being possessed in the period.

Finally on data, China continued to grapple with deepening deflation, marking its fastest pace in 15 years.

The consumer price index fell by 0.8% year-on-year in January, surpassing expectations and marking the fourth consecutive month of decline.

Food prices, particularly pork, contributed significantly to this contraction, with a 17% decrease in pork prices driving overall food price decline.

AstraZeneca slides, British American Tobacco climbs on results

On London's equity markets, pharmaceutical giant AstraZeneca slid 6.36% after announcing a 6% increase in sales for 2023, offset by a $3.7bn drop in Covid-19 medicine revenue.

While AstraZeneca projected robust growth for the year ahead, profits fell slightly short of analysts' expectations.

Digital 9 Infrastructure tumbled 21.98% after Icelandic authorities initiated an investigation into its proposed sale of Verne Global, while SSE was off 4.69% after a third-quarter trading statement.

Watches of Switzerland Group also saw a downturn of 2.46%, despite maintaining its full-year guidance, as third-quarter revenues dipped due to shifting consumer preferences.

On the upside, DS Smith rocketed 11.82% after confirming interest from rival Mondi.

Packaging sector peer Smurfit Kappa Group also experienced strong gains.

British American Tobacco climbed 7.12%, despite reporting a full-year loss attributed to an impairment charge.

Investors were encouraged by the company's successful performance in new categories, driving revenue growth.

"Usually, a company announcing losses running into the tens of billions of pounds wouldn't be cause for celebration among investors," said Russ Mould, investment director at AJ Bell.

"However, British American Tobacco has done just that this morning and been rewarded with share price gains.

"The impairments which have tipped British American Tobacco into a mega loss are non-cash items, relating to a write-down of the value of its acquisition of the part of Reynolds American it did not already own in 2017."

Mould said that while the size of the write-down had grown slightly, it was previously flagged in December.

"There was also a nugget of good news in today's results for the market to latch on to - the company has hit profitability with its 'new categories' products.

"These include its big vaping brands Vuse and Velo and these 'new categories' sales are seen as the company's answer to declining levels of cigarette smoking in the West."

Elsewhere, Unilever advanced 7.12% after announcing a €1.5bn share buyback, accompanied by a return to volume growth in the final quarter of 2023.

Compass Group rose 3.59% following a strong start to its financial year, with organic revenue surpassing full-year guidance.

Babcock International Group soared by 7.09% after JPMorgan raised its price target, citing increased earnings per share estimates post-capital markets day.

Finally, media business Future gained 3.08% despite reporting challenges in digital advertising revenues and foreign exchange fluctuations on Wednesday, as year-to-date trading remained broadly in line with expectations.

Reporting by Josh White for Sharecast.com.

Market Movers

FTSE 100 (UKX) 7,595.48 -0.44%

FTSE 250 (MCX) 19,102.72 -0.01%

techMARK (TASX) 4,393.75 -0.47%

FTSE 100 - Risers

Smith (DS) (SMDS) 308.60p 9.78%

British American Tobacco (BATS) 2,484.00p 7.12%

Smurfit Kappa Group (CDI) (SKG) 3,130.00p 5.32%

Unilever (ULVR) 4,024.50p 3.15%

Diploma (DPLM) 3,386.00p 2.92%

Compass Group (CPG) 2,211.00p 2.84%

3i Group (III) 2,382.00p 2.06%

Admiral Group (ADM) 2,531.00p 1.69%

Entain (ENT) 986.60p 1.46%

Experian (EXPN) 3,338.00p 1.46%

FTSE 100 - Fallers

AstraZeneca (AZN) 9,823.00p -6.36%

SSE (SSE) 1,575.50p -4.69%

Persimmon (PSN) 1,377.00p -4.31%

Mondi (MNDI) 1,336.50p -3.26%

Antofagasta (ANTO) 1,650.00p -2.80%

Coca-Cola HBC AG (CDI) (CCH) 2,188.00p -2.77%

Barratt Developments (BDEV) 487.50p -2.69%

JD Sports Fashion (JD.) 104.50p -2.65%

Standard Chartered (STAN) 579.40p -2.43%

Taylor Wimpey (TW.) 145.25p -2.35%

FTSE 250 - Risers

Ashmore Group (ASHM) 232.40p 9.93%

Babcock International Group (BAB) 459.20p 8.25%

Syncona Limited NPV (SYNC) 122.80p 6.23%

Me Group International (MEGP) 134.60p 4.34%

Tullow Oil (TLW) 30.04p 3.59%

Dr. Martens (DOCS) 86.95p 3.20%

Future (FUTR) 685.50p 3.08%

Bridgepoint Group (Reg S) (BPT) 267.20p 3.01%

Spirent Communications (SPT) 118.90p 2.85%

Diversified Energy Company (DEC) 935.00p 2.80%

FTSE 250 - Fallers

PZ Cussons (PZC) 100.60p -5.98%

Bluefield Solar Income Fund Limited (BSIF) 105.00p -3.49%

Darktrace (DARK) 347.90p -3.08%

Wizz Air Holdings (WIZZ) 2,114.00p -2.98%

Close Brothers Group (CBG) 465.40p -2.80%

Kainos Group (KNOS) 1,113.00p -2.62%

Pennon Group (PNN) 668.50p -2.55%

Watches of Switzerland Group (WOSG) 372.40p -2.46%

Aberforth Smaller Companies Trust (ASL) 1,310.00p -2.38%

Harbour Energy (HBR) 254.90p -2.22%

More News
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.